As abnormal expression and activation of AXL may promote chemotherapy resistance, cancer cell proliferation, invasion, and metastasis, blocking AXL pathways may enhance the sensitivity of cancer cells to cytotoxic agents and help to overcome the problem of resistance to EGFR TKIs [10, 12–15]. This evidence concerns the gene EGFR and cancer.